Amphotec liposomal amphotericin B data

Results of a retrospective trial in 82 patients were presented by researchers at the International Conference of Infectious Diseases in Hong Kong, using a 261-patient historical control group to show better survival and less toxicity with Amphotec than with free amphotericin B. Efficacy was 49 percent, compared to 23 percent for the historic controls. Survival rate at 120 days was 50 percent versus 28 percent. Nephrotoxicity was 43 percent in the control group but only 8 percent in those receiving Amphotec.

Amphotec doses ranged from 0.5 to 8 mg/kg/day. Both the Amphotec and control groups received at least seven days of treatment, and were balanced for underlying disease (blood malignancy, bone marrow transplant, organ transplant, or solid tumor). Most of the infections were proven or probable aspergillosis of the lung. ...